AstraZeneca Pharma India reported a 37% revenue increase for Q2 2025-26. The company also highlighted seven new drug approvals in the first half of the fiscal year. Growth momentum occurred across Oncology, Biopharmaceuticals, and Rare Diseases, strengthening AstraZeneca’s market position. This performance reflects the company’s commitment to scientific innovation and patient access.
Strong Financial Performance
AstraZeneca Pharma India Limited announced a revenue growth of 37% for the quarter ended September 30, 2025 (Q2 2025-26). This substantial growth reflects strong execution and positive momentum across key therapeutic areas.
Key Financial Highlights (INR Mn)
- Total Revenue (Q2 2025): 5,590.9
- Total Revenue (H1 2025): 10,854.0
- Profit Before Exceptional Items and Tax (Q2 2025): 781.1
- Profit After Exceptional Item and Tax (Q2 2025): 542.2
New Drug Approvals
The company achieved seven new regulatory approvals in the first half of the fiscal year, strengthening its leadership across various therapeutic areas. Key approvals include:
- Durvalumab: Approved for endometrial cancer and muscle-invasive bladder cancer (MIBC).
- Eculizumab: Launched for atypical Haemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH).
- Osimertinib: Approved for NSCLC in combination with chemotherapy and as a monotherapy.
- Trastuzumab deruxtecan: Approved for HER2-low and HER2-ultralow metastatic breast cancer.
- Benralizumab: Approved for eosinophilic granulomatosis with polyangiitis (EGPA).
Growth Across Key Therapeutic Areas
AstraZeneca experienced growth across its core therapeutic areas:
- Oncology: Driving significant revenue.
- Biopharmaceuticals (CVRM, R&I, V&I): Contributing strongly to overall growth.
- Rare Disease: Showing promising expansion.
Commitment to Innovation and Patient Access
AstraZeneca remains focused on translating cutting-edge science into life-changing medicines for patients in India, shaping a more accessible and outcomes-driven healthcare ecosystem.
Source: BSE
